A more recent version of this regulatory record is available. This version is kept only as a historical record. Please see the Record history section for link to the most recent version.
List details
Basic info
Status | Intention |
---|---|
Submitter | Ireland |
Regulatory programme |
|
Remarks | The substance was evaluated by Ireland in 2013 and the outcome of the substance evaluation was a recommendation for harmonised classification. |
Classification
Proposed harmonised classification by the dossier submitter |
|
---|
Intention timeline
Date of intention | 2020-08-19 |
---|---|
Expected date of submission | 2020-12-31 |
Documents
Related substances
By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.
Related regulatory records
Record history
The following timeline shows when we detected changes of this regulatory record (the date might slightly differ from the date of the actual change). Additions between versions are hightlighted in green color, red color shows data removed between versions.
Jan. 6, 2021
- Expected date of submission: 2020-12-31 → 2021-03-31
March 27, 2021
- Status: Intention → Submitted
- Submitted for accordance check: 2021-03-16
March 31, 2021
- Name: 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate → 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo [4.1.0]heptane-3-carboxylate
April 9, 2021
- Name: 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo [4.1.0]heptane-3-carboxylate → 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate
April 21, 2021
- Remarks: The substance was evaluated by Ireland in 2013 and the outcome of the substance evaluation was a recommendation for harmonised classification. → The substance was evaluated by Ireland in 2013 and the outcome of the substance evaluation process (2018) was a recommendation for harmonised classification for skin sens 1, STOT RE 2 and Muta 2.
May 11, 2021
- Remarks: The substance was evaluated by Ireland in 2013 and the outcome of the substance evaluation process (2018) was a recommendation for harmonised classification for skin sens 1, STOT RE 2 and Muta 2.
May 17, 2021
- Remarks: The substance was evaluated by Ireland in 2013 and the outcome of the substance evaluation process (2018) was a recommendation for harmonised classification for skin sens 1, STOT RE 2 and Muta 2.
Oct. 8, 2021
- Annexes to the CLH Report: https://echa.europa.eu/documents/10162/7bcbd585-7b68-2764-15d8-f6401ece9b0e
- CLH report: https://echa.europa.eu/documents/10162/1eb87587-ba15-4201-1e64-f85aa9c006d4
- Deadline for commenting: 2021-10-22
- Final submission date: 2021-07-15
- Hazard classes open for commenting: Skin sensitisation Germ cell mutagenicity Specific target organ toxicity — repeated exposure
- Legal deadline for opinion adoption: 2023-01-14
- Proposed specific concentration limits by the dossier submitter: H373 (nasal cavity)
- Status: Submitted → Consultation
- Start of consultation: 2021-08-23
Nov. 3, 2021
- Status: Consultation → Opinion Development
Nov. 9, 2021
- Comments received: https://echa.europa.eu/documents/10162/56c64621-5171-ffb2-bc0b-b513e848ea77
July 13, 2022
- Date of opinion: 2022-06-02
- Status: Opinion Development → Opinion Adopted
Aug. 31, 2022
- Background document: https://echa.europa.eu/documents/10162/266c5034-91dc-387f-196e-a379766f0587
- Comments received: https://echa.europa.eu/documents/10162/56c64621-5171-ffb2-bc0b-b513e848ea77 → https://echa.europa.eu/documents/10162/75faaf64-5ff4-2931-ac82-9c1f24c4025f
- RAC opinion: https://echa.europa.eu/documents/10162/1d79e978-f826-3a1e-c301-823af7c72513
This version
Add the related substance to your watchlist to monitor this regulatory record.